From the big three to the big four.

626 www.thelancet.com/infection Vol 15 June 2015 6 Bellan SE, Pulliam JRC, Pearson CAB, et al. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis 2015; published online April 15. http://dx.doi. org/10.1016/S1473-3099(15)70139-8. 7 The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group. Cancer Res 1987; 47: 5782–87. 8 Chowell G, Viboud C, Hyman JM, Simonsen L. The western Africa Ebola virus disease epidemic exhibits both global exponential and local polynomial growth rates. PLoS Curr Outbreaks 2015; published online Jan 21. DOI:10.1371/currents.outbreaks.8b55f4bad99ac5c5db366 3e916803261. 9 Faye O, Boelle PY, Heleze E, et al. Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study. Lancet Infect Dis 2015; 15: 320–26. 10 Fasina F, Shittu A, Lazarus D, et al. Transmission dynamics and control of Ebola virus disease outbreak in Nigeria, July to September 2014. Euro Surveill 2014; 19: 20920. 11 Lipsitch M, Eyal N, Halloran ME, et al. Vaccine testing. Ebola and beyond. Science 2015; 348: 46–48. 12 Grais RF, Conlan AJ, Ferrari MJ, et al. Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J R Soc Interface 2008; 5: 67–74.